Hyperthermic intravesical chemotherapy with gemcitabine versus Bacillus Calmette–Guerin in intermediate- and high-risk non-muscle-invasive bladder cancer
Among patients with intermediate- and high-risk NMIBC, hyperthermic intravesical chemotherapy combined with gemcitabine, compared with BCG treatment, significantly reduced the adverse events rate without compromising oncological survival outcomes. The primary limitations of this study are its small sample size and retrospective nature.
Authors
- Y. Li
- Tao Feng (ORCID: https://orcid.org/0000-0001-8550-0626)
- Shubo Chen
- Bing Yan (ORCID: https://orcid.org/0000-0002-1968-6693)
- Wenya Hu
- Lei Zhu
- Haifeng Xu
- Yuhua Qiao
Institutions
- Hebei Medical University (CN)
- Xingtai People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.3389/fonc.2025.1715762
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00